Back to Top Skip to main content

Defending the Homeland: Turning on lifesaving trials at Madigan Army Medical Center

Image of soldier in front of a laptop Janell Cain, a clinical research coordinator at Madigan with the Infectious Disease Clinical Research Program, records the informed consent forms signed by a patient receiving treatment for COVID-19 in the intensive care unit from Madigan’s Virtual Critical Care Center on April 14. Communicating with the patient and nurses via the video equipment, Cain gains the necessary consent to enroll a patient in a study of remdesivir as a COVID-19 treatment without expending personal protective equipment, or exposing anyone to the patient unnecessarily. The IDCRP is a Department of Defense-wide research consortium headquartered at the Uniformed Services University for the Health Sciences in Bethesda, Md. (Lt. Col. (Dr.) Christopher Colombo)

Recommended Content:

Coronavirus

MADIGAN ARMY MEDICAL CENTER, Joint Base Lewis-McChord, Wash. – Madigan Army Medical Center, on Joint Base Lewis-McChord, Wash., has been a hotbed for biomedical research for years, highlighted by patented innovations and award winning presentations at national and international scientific meetings.

In response to the COVID-19 global pandemic, Madigan is currently supporting nine research protocols designed to address gaps in knowledge including clinical characteristics of the COVID-19 illness, the impact of nutrition on COVID-19 risk, and the clinical value of convalescent plasma, in which a patient with severe disease is given plasma from someone who has recovered from COVID-19 and therefore has antibodies to it in their blood, to name a few.

Possibly the most notable clinical trial for COVID-19 treatment involves remdesivir, an investigational, broad-spectrum antiviral drug that has shown some promise, in animal trials, in both Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), which are caused by other coronaviruses.

The trial is sponsored by the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health, and is the first clinical trial in the U.S. to evaluate an experimental treatment for COVID-19.

When the trial began in February, Dr. Anthony Fauci, the director of NIAID and a member of the U.S. Coronavirus Task Force said, “We urgently need a safe and effective treatment for COVID-19. Although remdesivir has been administered to some patients with COVID-19, we do not have solid data to indicate it can improve clinical outcomes. A randomized, placebo-controlled trial is the gold standard for determining if an experimental treatment can benefit patients.”

Madigan is one of 68 international trial sites among 47 in the U.S. and 21 in Europe and Asia. The first enrollee was at the University of Nebraska Medical Center/Nebraska Medicine, in February; he had been on a cruise ship that saw a number of infections.

The initiation of the trial can is described here: https://www.niaid.nih.gov/news-events/nih-clinical-trial-remdesivir-treat-covid-19-begins.

Within two months of initiation, the clinical trial of remdesivir has produced encouraging results.

In a statement issued on April 29, the NIAID reported, “Preliminary results indicate that patients who received remdesivir had a 31 percent faster time to recovery than those who received placebo (p<0.001). Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo. Results also suggested a survival benefit, with a mortality rate of 8.0 percent for the group receiving remdesivir versus 11.6 percent for the placebo group (p=0.059).”

This trial is managed at Madigan by the Infectious Disease Clinical Research Program, a Department of Defense-wide research consortium headquartered at the Uniformed Services University for the Health Sciences in Bethesda, Md. The IDCRP conducts clinical research that focuses on reducing the impact of infectious diseases relevant to the DoD.

For more information about the IDCRP, visit: https://www.idcrp.org/about-us.

The IDCRP has a broad research portfolio, including an ongoing study looking at the efficacy of different formulations of the flu vaccine. When COVID-19 emerged, the IDCRP pivoted to get this research up and running in a very short period of time. As an established IDCRP site, Madigan was identified as one of the military treatment facilities eligible for participation in the NIAID trial.

“Because they are so active and such a squared-away group, they were able to help get this trial off the ground,” said Lt. Col. (Dr.) Christopher Colombo, principal investigator for the COVID-19 trial and the director of Virtual Health and Telecritical Care at Madigan.

Madigan has strong and adaptive biomedical research capabilities that are facilitated by its Department of Clinical Investigation.

“The Department of Clinical Investigation, Dr. Rick Burney (DCI’s chief) and Dr. (Silvija) Salai (the human subject protection administrator), have been fantastic in supporting and expediting this and balancing making sure that everything is still done dress-right-dress according to regulatory, safety and scientific integrity filings, but it is going quite a bit faster than usual, because of the situation that we're in,” noted Lt. Col. Colombo.

Madigan is one of five DoD sites that has enrolled patients in the study so far and is already ramping up for its next phase. Investigators stress that these are early days of evaluation for this trial. Given the high transmissibility and global spread of this virus, research has moved quickly.

“It's a placebo controlled trial, so the patients are randomized. We don't know who's getting what. They either get placebo or remdesivir,” Lt. Col. Colombo said.

NIH requirements for inclusion in the trial comprise the need for hospitalization for documented COVID-19 infection and either an abnormal chest x-ray or the requirement for supplemental oxygen or mechanical ventilation. Trial participation is limited to adults.

Participants in the treatment group get 200 milligrams (mg) of remdesivir injected on the first day they are in the study and 100 mg each day of their hospitalization, up to 10 days total. Those in the placebo group receive the same amount of what looks like remdesivir but contains only inactive ingredients.

This means the trial is administered to patients currently being treated in the hospital, though some have since improved and gone home. They return to the hospital periodically for monitoring.

Dr. Rhonda Colombo, an infectious diseases physician who works in support of the IDCRP at Madigan, praised the contributions of patients who volunteered to participate in this and other ongoing clinical research trials.

“Without willing and engaged study participants, clinical research is not possible. At Madigan, we are incredibly fortunate to be part of a community that values clinical research. Our research team is humbled by the generosity and commitment of the people who volunteer to participate in our studies,” said Dr. Colombo.

With drug safety and long-term effects always in mind, the team is not yet ready to draw conclusions, but is optimistic about the data so far.

Susan Chambers, the clinical operations manager for the IDCRP at Madigan echoed that appreciation for the high value that Madigan, and the JBLM community place on research, noting that it is the providers and nurses on the inpatient units who directly support research within their care of patients.

“We are incredibly proud to have the opportunity to offer access to cutting-edge research for our Active Duty personnel and DoD beneficiaries. Our success would not be possible without the support of Madigan Commander Col. Thomas Bundt and the committed inpatient clinical care teams at Madigan,” said Chambers.

On Friday, May 1, the U.S. Food and Drug Administration gave remdesivir emergency use authorization to treat COVID-19.

The NIAID expects to share additional data soon, as well as next steps.

“We managed to get meaningful research turned on, very quickly. Other sites in the Department of Defense, are kind of looking at Madigan like you guys are knocking it out of the park, keep going,” said Lt. Col. Colombo. “I think it's something that's cool in terms of how we're responding to COVID in a positive way and making some good come of this.”

Disclaimer: Re-published content may be edited for length and clarity.  Read original post.

You also may be interested in...

Navy pharmacy techs support COVID-19 and MHS GENESIS efforts

Article
10/20/2020
Navy personnel in a pharmacy

Hospital Corpsman 1st Class Aaron Souders is highlighted for his work as a Navy pharmacy technician.

Recommended Content:

Coronavirus | MHS GENESIS | Combat Support

Navy tele-health supports Guam civilian hospital during COVID-19

Article
10/19/2020
Woman sitting in front of several computer monitors

[T]his is the first-ever DoD tasking for telemedicine support in response to a request from civil authorities for aid.

Recommended Content:

Coronavirus | Combat Support | Global Health Engagement

Navy unit provided COVID-19 support to Peruvian First Responders

Article
10/16/2020
Fireman getting COVID test in firehouse garage

The province of Callao has the second highest number of COVID-19 cases in Peru.

Recommended Content:

Coronavirus | Global Health Engagement

COVID-19 Social Media Toolkit

Publication
10/16/2020

These messages are provided for you to use on your platforms with any of the images from the COVID-19 Toolkit.

Recommended Content:

Coronavirus

DHA Director outlines how MHS standardization bolsters reform

Article
10/15/2020
Two soldiers in masks, talking

How COVID-19 repositioned the best laid plans of the DoD.

Recommended Content:

Coronavirus | Joint Health Information Exchange | MHS GENESIS | MHS Transformation

Annual flu vaccine remains a health priority during COVID-19 era

Article
10/13/2020
Military personnel getting flu shot

Annual vaccine is a covered TRICARE benefit.

Recommended Content:

Immunization Healthcare | Vaccine-Preventable Diseases | Public Health | Coronavirus

Pilot DoD/VA hearing program virtually trains technicians

Article
10/9/2020
Military personnel sitting in front of laptop

HCE virtually trains hearing technicians during COVID-19.

Recommended Content:

Coronavirus | Hearing Loss

MHS Minute: Heroes Behind the Mask

Video
10/8/2020
Image of MHS Minute Carousel

In the face of a global threat, healthcare heroes across the MHS have donned their mask, and served on the front line of the battle against COVID-19. Tune in to this month's "MHS Minute" to learn more!

Recommended Content:

Coronavirus

‘I am Navy Medicine’ – helping another in need - Hospitalman Grace Pridmore of NMRTC Bremerton

Article
10/7/2020
Corpsman conviction of care, compassion and competence…Hospitalman Grace Pridmore, from Kellyville, Okla., assigned to Navy Medicine Readiness and Training Command (NMRTC) Bremerton Detachment Puget Sound Naval Shipyard (PSNS), was acknowledged for her selfless effort by Capt. Shannon J. Johnson, NMRTC Bremerton commanding officer, for identifying another Sailor at risk and taking quick action to help get the Sailor to the appropriate level of care, very possibly saving a life (official Navy photo by Douglas H Stutz, NHB/NMRTC Bremerton public affairs officer).

It takes more than just awareness to respond to someone showing signs of distress.

Recommended Content:

Coronavirus | Mental Health Care | Mental Wellness

DHA priorities focused on readiness, patients, outcomes

Article
10/7/2020
Defense Health Agency Director Army Lt. Gen. Ronald Place speaks at a podium.

Adaptation key to providing outstanding care to beneficiaries.

Recommended Content:

Health Readiness | Combat Support | Access to Health Care | Coronavirus | Convalescent Plasma Collection Program

Maintaining positive social media interactions during COVID-19

Article
10/2/2020
Image of soldier looking at his cell phone

Experts discuss good, bad of social media during pandemic.

Recommended Content:

Coronavirus

Defense Health Agency celebrates seven years of service

Article
10/1/2020
Lt. Gen. Ronald Place holding a wreath at Arlington National Cemetery

Seven ways DHA has improved military readiness over the years.

Recommended Content:

Defense Health Agency | Coronavirus | MHS Transformation | Technology | Global Health Engagement | TRICARE Health Program | Total Force Fitness

Easy steps to understanding & thwarting depression during COVID-19

Article
9/30/2020
Five people sitting on yoga mats outside in the grass

Learning self-care strategies can help you take charge of your life and improve your mental and physical health.

Recommended Content:

Coronavirus | Mental Health Care | Depression

Beale AFB clinic launches new EHR -- MHS GENESIS

Article
9/29/2020
Photo of Travis Callihan

This new EHR will provide a better level of care for all Department of Defense beneficiaries.

Recommended Content:

Coronavirus | MHS GENESIS

Army SHARP/SAPR’s awareness creates a safe culture at JBLE

Article
9/25/2020
Image of teal ribbon against soldier's uniform

Remaining on guard against sexual harassment/assault despite pandemic.

Recommended Content:

Coronavirus | Sexual Assault Prevention
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 18

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.